Other Titles

Maternal Health

Abstract

A woman with cystic fibrosis became pregnant twice on ivacaftor/lumacaftor after years of trying to conceive unsuccessfully. Safety profiles for this drug have not been established for pregnant women. Implications for research, practice, and education related to CF drug therapy are vast for this vulnerable group.

Author Details

Sigrid L. Ladores, PhD, RN, PNP, School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, USA

Sigma Membership

Unknown

Lead Author Affiliation

The University of Alabama at Birmingham, Birmingham, Alabama, USA

Type

Presentation

Format Type

Text-based Document

Study Design/Type

N/A

Research Approach

N/A

Keywords:

Cystic Fibrosis, Pregnancy, Targeted Therapeutics

Conference Name

29th International Nursing Research Congress

Conference Host

Sigma Theta Tau International

Conference Location

Melbourne, Australia

Conference Year

2018

Rights Holder

All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.

All permission requests should be directed accordingly and not to the Sigma Repository.

All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.

Acquisition

Proxy-submission

Additional Files

download (907 kB)

Share

COinS
 

Two unexpected pregnancies attributable to cystic fibrosis gene-specific drug therapy: A case study

Melbourne, Australia

A woman with cystic fibrosis became pregnant twice on ivacaftor/lumacaftor after years of trying to conceive unsuccessfully. Safety profiles for this drug have not been established for pregnant women. Implications for research, practice, and education related to CF drug therapy are vast for this vulnerable group.